AR057985A1 - Moduladores heterociclicos de la beta-secretasa, composiciones farmaceuticas y usos. - Google Patents
Moduladores heterociclicos de la beta-secretasa, composiciones farmaceuticas y usos.Info
- Publication number
- AR057985A1 AR057985A1 ARP060105083A ARP060105083A AR057985A1 AR 057985 A1 AR057985 A1 AR 057985A1 AR P060105083 A ARP060105083 A AR P060105083A AR P060105083 A ARP060105083 A AR P060105083A AR 057985 A1 AR057985 A1 AR 057985A1
- Authority
- AR
- Argentina
- Prior art keywords
- heteroatoms
- alkyl
- alkynyl
- alkenyl
- nr7c
- Prior art date
Links
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 title 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000005842 heteroatom Chemical group 0.000 abstract 28
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 18
- 125000000304 alkynyl group Chemical group 0.000 abstract 18
- 229910052717 sulfur Inorganic materials 0.000 abstract 17
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 abstract 16
- 108091008648 NR7C Proteins 0.000 abstract 16
- 229910052760 oxygen Inorganic materials 0.000 abstract 16
- -1 methoxy, ethyl Chemical group 0.000 abstract 15
- 125000004122 cyclic group Chemical group 0.000 abstract 14
- 125000002619 bicyclic group Chemical group 0.000 abstract 12
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 12
- 125000001424 substituent group Chemical group 0.000 abstract 12
- 125000004432 carbon atom Chemical group C* 0.000 abstract 10
- 125000001188 haloalkyl group Chemical group 0.000 abstract 10
- 125000002950 monocyclic group Chemical group 0.000 abstract 9
- 229910052757 nitrogen Inorganic materials 0.000 abstract 9
- 125000005309 thioalkoxy group Chemical group 0.000 abstract 9
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 8
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 7
- 125000003282 alkyl amino group Chemical group 0.000 abstract 7
- 125000004663 dialkyl amino group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 229920006395 saturated elastomer Polymers 0.000 abstract 5
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 4
- 125000004043 oxo group Chemical group O=* 0.000 abstract 4
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 abstract 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 3
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/68—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with nitrogen atoms directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Furan Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73910805P | 2005-11-21 | 2005-11-21 | |
| US85482406P | 2006-10-27 | 2006-10-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR057985A1 true AR057985A1 (es) | 2008-01-09 |
Family
ID=39708735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060105083A AR057985A1 (es) | 2005-11-21 | 2006-11-21 | Moduladores heterociclicos de la beta-secretasa, composiciones farmaceuticas y usos. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP1971598A1 (zh) |
| JP (1) | JP5274258B2 (zh) |
| AR (1) | AR057985A1 (zh) |
| AU (1) | AU2006316620B2 (zh) |
| CA (1) | CA2629402C (zh) |
| PE (1) | PE20070645A1 (zh) |
| TW (1) | TW200800966A (zh) |
| WO (1) | WO2007061670A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| TW200901991A (en) * | 2007-05-25 | 2009-01-16 | Amgen Inc | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| EP2167471B1 (en) * | 2007-05-25 | 2013-10-16 | Amgen Inc. | Substituted hydroxyethyl amine compounds as beta-secretase modulators and methods of use |
| CN103687839B (zh) | 2011-07-21 | 2016-06-08 | 通用电气健康护理有限公司 | 前体化合物及其制备方法 |
| US9493485B2 (en) | 2012-03-20 | 2016-11-15 | Imago Pharmaceuticals, Inc. | Spirocyclic dihydro-thiazine and dihydro-oxazine BACE inhibitors, and compositions and uses thereof |
| US9932333B2 (en) | 2014-07-16 | 2018-04-03 | Japan Science And Technology Agency | Benzothiazole compound and medicine containing same |
| TW202100526A (zh) | 2019-03-06 | 2021-01-01 | 日商第一三共股份有限公司 | 吡咯并吡唑衍生物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY138097A (en) | 2000-03-22 | 2009-04-30 | Du Pont | Insecticidal anthranilamides |
| MXPA02012560A (es) | 2000-06-30 | 2003-05-14 | Elan Pharm Inc | Compuestos para tratar la enfermedad de alzheimer. |
| US7196163B2 (en) | 2001-05-22 | 2007-03-27 | Merk & Co., Inc. | Assays using amyloid precursor proteins with modified β-secretase cleavage sites to monitor β-secretase activity |
| US6982264B2 (en) | 2001-06-27 | 2006-01-03 | Elan Pharmaceuticals, Inc. | Substituted alcohols useful in treatment of Alzheimer's disease |
| KR100713137B1 (ko) | 2001-06-28 | 2007-05-02 | 동화약품공업주식회사 | 신규의 2,4-디플루오로벤즈아미드 유도체 |
| MXPA04000338A (es) | 2001-07-10 | 2004-07-23 | Upjohn Co | Diamindioles para tratamiento de enfermedad de alzheimer. |
| CA2453447A1 (en) | 2001-07-10 | 2003-01-23 | Elan Pharmaceuticals, Inc. | Alpha-hydroxyamide statine derivatives for the treatment of alzheimer's disease |
| EP1409450B1 (en) | 2001-07-11 | 2009-12-09 | Elan Pharmaceuticals, Inc. | N-(3-amino-2-hydroxy-propyl) substituted alkylamide compounds |
| US7244755B2 (en) | 2001-10-04 | 2007-07-17 | Pharmacia & Upjohn Company | Hydroxypropylamines |
| AU2002335794A1 (en) | 2001-10-05 | 2003-04-22 | Elan Pharmaceuticals, Inc | Allylamides useful in the treatment of alzheimer's disease |
| JP2005535559A (ja) | 2001-10-29 | 2005-11-24 | ファルマシア・アンド・アップジョン・カンパニー・エルエルシー | アルツハイマー病を治療するためのヒドロキシ置換アミド |
| EP1453789A2 (en) | 2001-11-08 | 2004-09-08 | Elan Pharmaceuticals, Inc. | N,n'-substituted-1,3-diamino-2-hydroxypropane derivatives |
| TW200304374A (en) | 2001-11-30 | 2003-10-01 | Smithkline Beecham Plc | Novel compounds |
| BR0214736A (pt) | 2001-12-06 | 2004-11-23 | Elan Pharm Inc | Composto e seus sais farmaceuticamente aceitáveis, composição farmacêutica e método de tratar seres humanos ou animais que sofrem de doenças ou condições |
| JP2005534614A (ja) | 2002-01-04 | 2005-11-17 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病治療のための置換アミノカルボキサミド |
| EP1471910A2 (en) | 2002-01-17 | 2004-11-03 | Neurogen Corporation | Substituted quinazolin-4-ylamine analogues as modulators of capsaicin receptors |
| AU2003276047A1 (en) | 2002-06-17 | 2003-12-31 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
| US7115747B2 (en) | 2002-06-20 | 2006-10-03 | Pharmacia & Upjohn Company | Process for preparing oxazole intermediates |
| UY27967A1 (es) | 2002-09-10 | 2004-05-31 | Pfizer | Acetil 2-hindroxi-1,3-diaminoalcanos |
| US7362070B2 (en) | 2002-11-04 | 2008-04-22 | Hamilton Sundstrand Corporation | Electric motor control system including position determination and error correction |
| CA2505098A1 (en) | 2002-11-12 | 2004-05-27 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer's disease |
| WO2004050609A1 (en) * | 2002-11-27 | 2004-06-17 | Elan Pharmaceutical, Inc. | Substituted ureas and carbamates |
| GB0228410D0 (en) | 2002-12-05 | 2003-01-08 | Glaxo Group Ltd | Novel Compounds |
| CA2512111A1 (en) | 2003-01-07 | 2004-07-29 | Merck And Co., Inc. | Macrocyclic beta-secretase inhibitors for treatment of alzheimer's disease |
| US20060241133A1 (en) | 2003-03-14 | 2006-10-26 | Shearman Mark S | Electrically variable pneumatic structural element |
| GB0305918D0 (en) | 2003-03-14 | 2003-04-23 | Glaxo Group Ltd | Novel compounds |
| CA2522805A1 (en) * | 2003-04-21 | 2004-11-04 | Elan Pharmaceuticals, Inc. | Phenacyl 2-hydroxy-3-diaminoalkanes |
| MXPA05011150A (es) | 2003-04-21 | 2005-12-14 | Elan Pharm Inc | 2-hidroxi-3-diaminoalcanos de benzamida. |
| GB0309221D0 (en) * | 2003-04-23 | 2003-06-04 | Glaxo Group Ltd | Novel compounds |
| WO2005005374A1 (en) | 2003-06-16 | 2005-01-20 | Sunesis Pharmaceuticals, Inc. | Aspartyl protease inhibitors |
| CN100430377C (zh) | 2003-06-30 | 2008-11-05 | 麦克公司 | 用于治疗阿尔茨海默病的N-烷基苯基甲酰胺β分泌酶抑制剂 |
| EP1643986A4 (en) | 2003-07-01 | 2009-04-08 | Merck & Co Inc | PHENYL ACARBOXYLATE BETA SECRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER |
| GB0317491D0 (en) * | 2003-07-25 | 2003-08-27 | Novartis Ag | Organic compounds |
| JP2007522129A (ja) * | 2004-01-21 | 2007-08-09 | エラン ファーマシューティカルズ，インコーポレイテッド | アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法 |
| JP2007528403A (ja) * | 2004-03-09 | 2007-10-11 | エラン ファーマシューティカルズ，インコーポレイテッド | 二環式アスパラギン酸プロテアーゼ阻害薬を用いるアミロイドーシスの処置方法 |
| JP2007530583A (ja) * | 2004-03-25 | 2007-11-01 | イーラン ファーマスーティカルズ、インコーポレイテッド | ２−アミノ−及び２−チオ置換されている１，３−ジアミノプロパン |
-
2006
- 2006-11-13 JP JP2008541258A patent/JP5274258B2/ja not_active Expired - Fee Related
- 2006-11-13 AU AU2006316620A patent/AU2006316620B2/en not_active Ceased
- 2006-11-13 CA CA2629402A patent/CA2629402C/en not_active Expired - Fee Related
- 2006-11-13 EP EP06837478A patent/EP1971598A1/en not_active Withdrawn
- 2006-11-13 WO PCT/US2006/044058 patent/WO2007061670A1/en not_active Ceased
- 2006-11-20 PE PE2006001476A patent/PE20070645A1/es not_active Application Discontinuation
- 2006-11-21 TW TW095143035A patent/TW200800966A/zh unknown
- 2006-11-21 AR ARP060105083A patent/AR057985A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20070645A1 (es) | 2007-08-24 |
| JP2009516684A (ja) | 2009-04-23 |
| TW200800966A (en) | 2008-01-01 |
| CA2629402C (en) | 2011-07-26 |
| WO2007061670A1 (en) | 2007-05-31 |
| JP5274258B2 (ja) | 2013-08-28 |
| EP1971598A1 (en) | 2008-09-24 |
| CA2629402A1 (en) | 2007-05-31 |
| AU2006316620A1 (en) | 2007-05-31 |
| AU2006316620B2 (en) | 2011-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR068051A1 (es) | Compuestos moduladores de la pi3k quinasa,composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del cancer. | |
| AR071617A1 (es) | Bencenosulfonamidas de oxazol y tiazol, composiciones farmaceuticas que las contienen, proceso de preparacion y uso de las mismas como agentes anticancerigenos. | |
| AR083199A1 (es) | Compuestos de n-heteroarilo con unidad de puente ciclico | |
| AR058546A1 (es) | Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1 | |
| AR061581A1 (es) | Compuestos de pirro[1,2-b]piridazinona,composiciones farmaceuticas que los contienen y usos para tratar hepatitis c. | |
| AR081653A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR045529A1 (es) | Imidazoquinolinas sustituidas con grupos ariloxi o arilalquilenoxi | |
| AR053443A1 (es) | Compuestos de ftalazina aza- y diaza-ftalazina y metodos de uso | |
| AR082153A1 (es) | N-sulfonilbenzamidas utiles como inhibidor del canal de sodio | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| AR081932A1 (es) | Derivados de heteroaril imidazolona, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades neoplasicas y autoinmunes | |
| AR058065A1 (es) | Compuestos de carboxiamina y uso de los mismos.composiciones farmaceuticas. | |
| AR068054A1 (es) | Compuestos de pirrolopirimidina | |
| AR068503A1 (es) | Derivados de amidas sustituidas, composicion farmaceutica y usos. | |
| AR038888A1 (es) | Amidas heterociclicas | |
| AR082152A1 (es) | Derivados de n-(metilsulfonil)benzamida, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de nav1.7 | |
| CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
| AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
| PE20011166A1 (es) | Piridinas, pirimidinas, purinonas, pirrolopirimidinonas y pirrolopiridinonas como antagonistas del factor liberador de corticotropina | |
| AR048641A1 (es) | Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame | |
| AR075005A1 (es) | Derivados de sulfonamida | |
| RU2012140961A (ru) | ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ | |
| AR081649A1 (es) | Compuestos heteroarilo nitrogenados |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |